Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

Author information

Affiliations

  • 1. Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK.
      Authors
    • Mbidde EK 1
    (1 author)

ORCIDs linked to this article

British Journal of Cancer, 01 Dec 1988, 58(6):779-782
https://doi.org/10.1038/bjc.1988.308 PMID: 2852028 PMCID: PMC2246887

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.

Free full text 

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1988 Dec; 58(6): 779–782.
PMCID: PMC2246887
PMID: 2852028

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

E. K. Mbidde, P. J. Selby, T. J. Perren, D. P. Dearnaley, A. Whitton, S. Ashley, P. Workman, H. J. Bloom, and T. J. McElwain
Author information Copyright and License information Disclaimer

Abstract

In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (821K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 779
779
icon of scanned page 780
780
icon of scanned page 781
781
icon of scanned page 782
782
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bloom HJ. Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980. Int J Radiat Oncol Biol Phys. 1982 Jul;8(7):1083–1113. [Abstract] [Google Scholar]
  • Cornbleet MA, McElwain TJ, Kumar PJ, Filshie J, Selby P, Carter RL, Hedley DW, Clark ML, Millar JL. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer. 1983 Sep;48(3):329–334. [Europe PMC free article] [Abstract] [Google Scholar]
  • Fingert HJ, Hochberg FH. Megadose chemotherapy with bone marrow rescue. Prog Exp Tumor Res. 1984;28:67–78. [Abstract] [Google Scholar]
  • Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J, Jr, Odom GL, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983 Feb;67(2):121–132. [Abstract] [Google Scholar]
  • Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E., 3rd Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep. 1986 Jul;70(7):877–880. [Abstract] [Google Scholar]
  • Phillips GL, Wolff SN, Fay JW, Herzig RH, Lazarus HM, Schold C, Herzig GP. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol. 1986 May;4(5):639–645. [Abstract] [Google Scholar]
  • Walker MD, Green SB, Byar DP, Alexander E, Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Jr, Mealey J, Jr, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323–1329. [Abstract] [Google Scholar]
  • Wolff SN, Phillips GL, Herzig GP. High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system. Cancer Treat Rep. 1987 Feb;71(2):183–185. [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Full text links 

Read article at publisher's site: https://doi.org/10.1038/bjc.1988.308

Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc2246887?pdf=renderUnpaywall

Citations & impact 

Impact metrics

32
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (32) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.